Three Stocks to Buy on the Dips: CYTX, SUNH, RECN
Cytori Therapeutics (CYTX) Gains Amidst Challenges; Sun Healthcare (SUNH) Near its High on a Good Quarter; Resources Connection (RECN) Rises with IASeminars.
0 Comment(s)
 |
Find a Stock's Home Page |
|
| Small Cap Stock Analysis |
Attention China Investors: BSPM An Easy Double For Smart Money
Biostar Pharmaceuticals, Inc. (OTCBB: BSPM) looks like it could follow these many other china stocks from rags to riches. BSPM is notching monster profits and growth by helping solve one monster problem - the spread of Hepatitis B in China.
The Future’s So Bright You’ve Got to Wear Shades: YTEC, AFFX, LF
Yucheng Technologies (YTEC) Turns Around; Affymetrix (AFFX) Gets a New CFO; LeapFrog Enterprises (LF) Gains and Gains on Education Reform.
Why Buyers are Flocking to these Stocks: IMMU, EXEL, ULTI
Immunomedics (IMMU) Powers Up on Patents; Exelixis (EXEL) Gains on Cost Cutting; Ultimate Software (ULTI) Rallies on New Sales Deals.
Don’t Get Left Behind: HEV, AEIS, CERS
Ener1 (HEV) Gains on New Orders; Advanced Energy (AEIS) Makes a Strong Comeback; Cerus (CERS) Moves Up on Product Viability.
Undervalued and Priced to Buy: ATAI, ZOLT, RDNT
ATA (ATAI) Share Buyback Propels Stock; Zoltek (ZOLT) Gains on Danish Award; RadNet (RDNT) Gains on Today’s Quarterly Report Anticipation.
Buying Copper and Real Estate in China: FSIN, DXCM, CRIC
Fushi Copperweld (FSIN) Gains on Copper in China; DexCom (DXCM) Rises on Better Year-Over-Year Results; China Real Estate (CRIC) Continues IPO Momentum.
Creating and Stirring Up Excitement: ALTH, CPWM, IFSIA
Allos Therapeutics (ALTH) Gains on Folotyn Drug Potential; Cost Plus (CPWM) Jumps on Management Changes; Interface (IFSIA) Moves Up on Debt Removal.
Three Buys Analysts and Pundits Love: CHINA, CRME, CHOP
CDC Corporation (CHINA) Buys Back Shares; Cardiome (CRME) Climbs on Drug Candidates; China Gerui (CHOP) Advances on China’s Production Needs.
Three Bio-Pharmas You Should Buy: SVA, MAPP, CYCC
Sinovac Biotech (SVA) Gains on Production Investment; Map Pharmaceuticals (MAPP) Rises on Levadex; Cyclacel Pharmaceuticals (CYCC) Jumps on Cancer Study.
